BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Noncurrent Value-Added Tax (VAT) Receivable by Year
Noncurrent Value-Added Tax (VAT) Receivable ($M) ($M)
BeOne Medicines Noncurrent Value-Added Tax (VAT) Receivable: $3.50M in FY2025, up 20.7% from a year earlier.
Latest, FY2025
3.50
Period ended Dec 31, 2025
Change on a year earlier
+20.7%
2.90 in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Balance Sheet Details Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Noncurrent Value-Added Tax (VAT) Receivable ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.50 | +20.7% | Form 10-Q (filed 2026-08-05) ↗ |
| FY2024 | Dec 31, 2024 | 2.90 | +16.0% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 2.50 | +212.5% | Form 10-K (filed 2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 0.80 | -95.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 17.2 | +57.8% | Form 10-K (filed 2023-02-27) ↗ |
| FY2020 | Dec 31, 2020 | 10.9 | -63.7% | Form 10-K (filed 2022-02-28) ↗ |
| FY2019 | Dec 31, 2019 | 30 | +104.1% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 14.7 | – | Form 10-K (filed 2020-03-02) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2019-02-28) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Noncurrent Value-Added Tax (VAT) Receivable ($M), annual FY2017–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/vat-rec-nc
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.